Sunitinib

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Adrenocortical Carcinoma

Conditions

Adrenocortical Carcinoma

Trial Timeline

Jul 1, 2007 → Feb 1, 2012

NCT ID

NCT00453895

About Sunitinib

Sunitinib is a phase 2 stage product being developed by Pfizer for Adrenocortical Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00453895. Target conditions include Adrenocortical Carcinoma.

What happened to similar drugs?

0 of 1 similar drugs in Adrenocortical Carcinoma were approved

Approved (0) Terminated (0) Active (1)

🔄OSI-906Astellas PharmaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05745142	Pre-clinical	Completed	Feb 23, 2023	Feb 23, 2023	Carcinoma, Renal Cell
NCT04115189	Pre-clinical	Completed	Dec 13, 2019	Dec 2, 2020	Metastatic Renal Cell Carcinoma ( mRCC)
NCT04175262	Pre-clinical	Completed	Oct 31, 2019	Mar 9, 2020	Metastatic Renal Cell Carcinoma (mRCC)
NCT04076787	Pre-clinical	Completed	Sep 1, 2018	Sep 2, 2018	Metastatic Renal Cell Carcinoma
NCT03592199	Phase 2	UNKNOWN	Dec 11, 2017	Dec 11, 2022	Clear Cell Renal Cell Carcinoma
NCT03140176	Pre-clinical	Terminated	Aug 15, 2017	Jan 22, 2022	Metastatic Renal Cell Carcinoma
NCT03066427	Phase 2	Completed	May 10, 2017	Sep 22, 2020	Clear Cell Renal Carcinoma
NCT02713763	Phase 2	Completed	Feb 14, 2017	Oct 23, 2019	Pancreatic Neuroendocrine Tumour Metastatic
NCT02689167	Phase 2	UNKNOWN	Feb 19, 2016	Feb 1, 2024	Kidney Neoplasms
NCT02282059	Pre-clinical	Completed	Dec 12, 2014	Dec 12, 2022	Pancreatic Neuroendocrine Tumors
NCT02060370	Phase 2	Completed	Aug 1, 2014	Jan 2, 2019	Genitourinary Cancer
NCT01525550	Approved	Completed	Jun 6, 2012	Jul 26, 2018	Well-differentiated Pancreatic Neuroendocrine Tumor
NCT01499121	Phase 2	Completed	May 1, 2012	Sep 30, 2017	Clear Cell, Metastatic Renal Cell Carcinoma
NCT01286896	Phase 1	Completed	Apr 11, 2011	Dec 27, 2011	Malignant Solid Tumour
NCT01070186	Phase 2	Withdrawn	Oct 1, 2010	—	Renal Cell Carcinoma
NCT01121562	Phase 2	Completed	Jul 1, 2010	Nov 1, 2013	Pancreatic Neuroendocrine Tumors
NCT01033981	Pre-clinical	Terminated	May 1, 2010	Feb 1, 2011	Metastatic Renal Cell Carcinoma
NCT01054911	Pre-clinical	Terminated	Oct 1, 2009	Sep 1, 2015	Tumor
NCT01042795	Phase 2	Terminated	Sep 1, 2009	Jan 1, 2013	Urothelial Carcinoma
NCT01069770	Phase 2	UNKNOWN	Jul 1, 2009	Jun 1, 2012	Clear Cell Renal Cell Carcinoma

Competing Products

6 competing products in Adrenocortical Carcinoma

See all competitors

Product	Company	Stage	Hype Score
DS9051b	Daiichi Sankyo	Phase 1	36
OSI-906	Astellas Pharma	Phase 3	40
Iressa (ZD1839)	AstraZeneca	Phase 2	35
Pembrolizumab	Merck	Phase 2	39
BGG492	Novartis	Phase 2	35
Relacorilant + Pembrolizumab	Corcept Therapeutics	Phase 1	26